
250660US40



WE (I) the undersigned inventor(s), hereby declare(s) that:

My residence, post office address and citizenship are as stated below next to my name,

We (I) believe that we are (I am) the original, first and joint (sole) inventor(s) of the subject matter which is claimed and for which a patent is sought on the invention entitled

## NASALLY ADMINISTRABLE COMPOSITIONS OF ZOLPIDEM AND METHODS OF USE the specification of which is attached hereto. Application Serial No. 10/801,856 and amended on \_\_\_\_ was filed as PCT international application Number and was amended under PCT Article 19 on \_\_\_\_\_ (if applicable). We (I) hereby state that we (I) have reviewed and understand the contents of the above-identified specification, including the claims, as amended by any amendment referred to above. We (I) acknowledge the duty to disclose information known to be material to the patentability of this application as defined in Section 1.56 of Title 37 Code of Federal Regulations. We (I) hereby claim foreign priority benefits under 35 U.S.C. §119(a)-(d) or §365(b) of any foreign application(s) for patent or inventor's certificate, or §365(a) of any PCT International application which designated at least one country other than the United States, listed below and have also identified below, by checking the box, any foreign application for patent or inventor's certificate, or PCT International application having a filing date before that of the application on which priority is claimed. Prior Foreign Application(s) **Priority** Application No. Country Day/Month/Year Claimed

☐ Yes

We (I) hereby claim the benefit under Title 35, United States Code, §119(e) of any United States provisional application(s) listed below.		
60/454,619		March 17, 2003
(Application Number)		(Filing Date)
(Application Number)		(Filing Date)
PCT International application designating the claims of this application is not discled provided by the first paragraph of 35 U.S.	g the United States, listed osed in the prior United Stace. §112, I acknowledge to which became available	Inited States application(s), or under §365(c) of any below and, insofar as the subject matter of each of ates or PCT International application in the manner he duty to disclose information which is material to between the filing date of the prior application and
Application Serial No.	Filing Date	Status (pending, patented, abandoned)
And we (I) hereby appoint the following registered practitioner(s):  Customer Number  22850  as our (my) attorneys, with full powers of substitution and revocation, to prosecute this application and to transact all business in the Patent Office connected therewith; and we (I) hereby request that all correspondence regarding this		
application be sent to		
Customer Number		
22850		
on information and belief are believed to willful false statements and the like so n	be true; and further that the nade are punishable by fin	In knowledge are true and that all statements made these statements were made with the knowledge that the or imprisonment, or both, under Section 1001 of ments may jeopardize the validity of the application
Stephen J. KRAMER	Res	sidence: c/o Fabre-Kramer Pharmaceuticals, Inc.
NAME OF FIRST OR SOLE INVENTOR  Signature of Inventor	OR	47 San Felipe, Suite 3147
	Но	ouston, TX 77057
	Cit	tizen of: USA
	Ma	ailing Address: c/o Fabre-Kramer
	Ph	armaceuticals, Inc.
JULY 27, 2004	584	47 San Felipe, Suite 3147
Date	Ho	ouston, TX 77057

Louis F. FABRE

NAME OF SECOND JOINT INVENTOR

Signature of Inventor

Residence: c/o Fabre-Kramer Pharmaceuticals, Inc.

5847 San Felipe, Suite 3147

Houston, TX 77057

Citizen of: USA

Mailing Address: c/o Fabre-Kramer

Pharmaceuticals, Inc.

5847 San Felipe, Suite 3147

Houston, TX 77057